Krazati Side Effects

Generic name: adagrasib

Medically reviewed by Drugs.com. Last updated on Aug 24, 2024.

Note: This document provides detailed information about Krazati Side Effects associated with adagrasib. Some dosage forms listed on this page may not apply specifically to the brand name Krazati.

Applies to adagrasib: oral tablet.

Serious side effects of Krazati

Along with its needed effects, adagrasib (the active ingredient contained in Krazati) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking adagrasib:

More common side effects

• agitation
• bloody urine
• bone pain
• chest pain, discomfort, or tightness
• coma
• confusion
• constipation
• cough
• dark urine
• decreased amount of urine
• depression
• diarrhea
• dizziness
• fainting
• fast heartbeat
• fever or chills
• headache
• hostility
• increased blood pressure
• increased thirst
• irregular or slow heart rate
• irritability
• lethargy
• lightheadedness
• loss of appetite
• lower back or side pain
• muscle twitching
• nausea
• rapid, shallow breathing
• seizures
• sneezing
• sore throat
• stomach pain, severe
• stupor
• swelling
• swelling of the face, fingers, or lower legs
• trouble breathing
• unusual tiredness or weakness
• vomiting
• weight gain
• yellow eyes or skin

Less common side effects

• anxiety
• blue lips, fingernails, or skin
• blurred vision
• coughing up blood
• decreased appetite
• decreased urination
• decreased weight
• dilated neck veins
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• dry mouth
• muscle pain or cramps
• nightmares or unusually vivid dreams
• pale skin
• sunken eyes
• sweating
• unusual bleeding or bruising
• wrinkled skin

Rare side effects

• inability to speak
• slurred speech
• stiffness
• temporary blindness
• weakness in the arm or legs on one side of the body, sudden and severe

Incidence not known

• general feeling of discomfort or illness
• thickening of bronchial secretions

For healthcare professionals

Applies to adagrasib: oral tablet.

General adverse events

The most common adverse reactions with a frequency of 25% or greater were nausea (70%), diarrhea (69%), vomiting (57%), fatigue (55%), musculoskeletal pain (38%), hepatotoxicity (37%), renal impairment (33%), edema (30%), dyspnea (26%), and decreased appetite (29%).

The most common Grade 3 or 4 laboratory abnormalities with a frequency of 2% or greater were decreased lymphocytes (20%), decreased sodium (52%), decreased hemoglobin (51%), increased alanine aminotransferase (4.5%), increased aspartate aminotransferase (4.2%), hypokalemia (3.6%), hyponatremia (3.4%), increased lipase (2.5%), decreased leukocytes (2.5%), decreased neutrophils (2.3%), and increased alkaline phosphatase (2.0%).^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (70%), nausea (70%), vomiting (57%), constipation (22%), abdominal pain (21%), increased lipase (35%)
• Uncommon (0.1% to 1%): Gastrointestinal obstruction
• Frequency not reported: Increased amylase^[Ref]

Cardiovascular

• Very common (10% or more): Electrocardiogram QT prolonged (20%)
• Common (1% to 10%): Cardiac failure, hypotension
• Uncommon (0.1% to 1%): Decreased ejection fraction, hemorrhage^[Ref]

Hematologic

• Very common (10% or more): Decreased lymphocytes (64%), decreased hemoglobin (51%), decreased platelets (27%)
• Common (1% to 10%): Anemia, decreased leukocytes, decreased neutrophils^[Ref]

Metabolic

• Very common (10% or more): Decreased appetite (30%)
• Common (1% to 10%): Hyponatremia, dehydration, hypokalemia^[Ref]

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (41%)
• Common (1% to 10%): Muscular weakness^[Ref]

Nervous system

• Very common (10% or more): Dizziness (23%)
• Common (1% to 10%): Cerebrovascular accident
• Uncommon (0.1% to 1%): Encephalitis^[Ref]

Other

• Very common (10% or more): Fatigue (59%), edema (32%), decreased sodium (52%), decreased albumin (50%), decreased magnesium (26%), decreased potassium (26%)
• Common (1% to 10%): Sudden death, sepsis, pyrexia, increased alkaline phosphatase
• Frequency not reported: Decreased weight^[Ref]

Psychiatric

• Common (1% to 10%): Mental status changes^[Ref]

Renal

• Very common (10% or more): Renal impairment (36%), increased creatinine (50%)^[Ref]

Renal impairment includes acute kidney injury and increased blood creatinine.^[Ref]

Respiratory

• Very common (10% or more): Dyspnea (35%), cough (24%), pneumonia (24%)
• Common (1% to 10%): Hypoxia, pleural effusion, respiratory failure
• Uncommon (0.1% to 1%): Pulmonary embolism, pulmonary hemorrhage, pneumonitis^[Ref]

Hepatic

• Very common (10% or more): Hepatotoxicity (37%), increased aspartate aminotransferase (52%), increased alanine aminotransferase (46%)^[Ref]

Hepatotoxicity includes, mixed liver injury, increased blood alkaline phosphatase, increased alanine aminotransferase, increased aspartate aminotransferase, increased liver function test, increased blood bilirubin, and increased conjugated bilirubin.^[Ref]

Further information

Krazati side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer